Minocin (minocycline) for Injection

DRUG2 trials

Sponsors

Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)

Conditions

Healthy SubjectsNormal Healthy VolunteersRenal Insufficiency, AcuteRenal Insufficiency, Chronic

Phase 1

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Minocin (Minocycline) for Injection in Healthy Adults

CompletedNCT02802631

Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)Normal Healthy Volunteers

Start: 2017-04-20End: 2018-02-08Updated: 2023-12-15

Evaluate Safety and Pharmacokinetics of Minocin (Minocycline) for Injection in Subjects With Renal Insufficiency

TerminatedNCT02808052

Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)Healthy Subjects, Renal Insufficiency, Acute, Renal Insufficiency, Chronic

Start: 2017-05-29End: 2018-06-04Updated: 2019-09-04